logo
Injured bald eagle, healed with fish skin, released back into the wild

Injured bald eagle, healed with fish skin, released back into the wild

USA Today3 days ago
Veterinarians saved the raptor from a devastating leg injury using a pioneering fish skin treatment. They released her back to freedom days before Independence Day.
A badly injured bald eagle saved by a pioneering fish skin treatment is back in the wild, just in time for the Fourth of July.
The bird, named Kere, was on the verge of death when volunteers brought her to the Winged Freedom Raptor Hospital in northern Wisconsin last August. Her leg was ripped open from knee to ankle, and maggots and bacteria had begun to fill the dried-out wound.
'It was horrendous,' said Veterinarian Kim Ammann. But the doctor saw a flicker of hope: the eagle was somehow standing on the bandaged-up leg, and its talons still worked.
'That's when I started to figure I was going to need something to close the wound,' said Ammann
A few Google searches later, Ammann stumbled on the Icelandic company Kerecis, which transplants the skin of North Atlantic cod to help heal human wounds and support tissue regeneration. The treatment had never been used on a species of raptor before, but Ammann took a leap and sent them an email.
Almost 'immediately,' she said the company reached back out and offered the descaled, medical fish skin free of charge to the all-volunteer veterinary hospital.
Within weeks, Ammann gave Kere, who is named in honor of the company, the first of two successful surgical skin grafts. The rest of her recovery included about 10 months of grueling wound care, bandage changes, and a mini vacation in the hospital's Eagle flyway rehabilitation enclosure.
'There was something very special about the fact that she was an eagle and that she was allowing me to do this,' Ammann said of the bird. 'That tolerance was part of what made it possible.'
By June 22, the wild bald eagle was ready to soar free again. The date was more about ensuring Kere had 'the majority of the summer months' to reacclimate with being wild again. But the symbolism of releasing a bald eagle so close to the Fourth of July wasn't lost on Ammann
A group of about a hundred viewers gathered to watch Kere take flight above the forests and fields. Amann described the day as 'magical.'
'She could decide whether she wanted to go east or west. She could decide what lake she wanted to go to,' Ammann said. 'I was so happy for her to have her independence back.'
A conservation success story
Bald eagles, an iconic symbol of the United States, are among the most protected species in the country.
But they haven't always been.
The bird's population began plummeting in the late 1800s as American industrialization began changing the landscape, destroying their habitats and introducing lead into the environment.
In 1940, the federal government enacted The Bald and Golden Eagle Protection Act prohibiting people from hunting, selling or possessing an eagle ‒ in effort to prevent further population decline.
But decades later, pesticides, including DDT, seeped into waterways and further endangered the species. The chemicals were believed to thin bald eagle eggs, decreasing the bird's reproductive success. The bald eagle population hit an all-time low in the 1960s, with just 417 nesting pairs in the continental U.S, according to the Smithsonian's National Zoo and Conservation Biology Institute.
The United States banned DDT in 1972 and passed The Endangered Species Act in 1973, to protect quickly disappearing species like the bald eagle. The raptor was taken off the endangered species list in 2007 as conservation efforts led to a population surge.
Today, there are an estimated 316,000 bald eagles in the lower 48 states. And in 2024, they became the country's national bird .
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Shocking Truth About Eating Ultra-Processed Foods And Your Lifespan, According To A New Study
The Shocking Truth About Eating Ultra-Processed Foods And Your Lifespan, According To A New Study

Yahoo

timean hour ago

  • Yahoo

The Shocking Truth About Eating Ultra-Processed Foods And Your Lifespan, According To A New Study

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A new study suggests that eating lots of ultra-processed foods can increase risk of death up to 10 percent. The findings were based on more than 540,000 American adults who tracked their diets for nearly 30 years. Here's what experts want you to know about UPFs and their impact on your health. Whether you're grabbing a quick deli meat sandwich from the grocery store or sipping on a soda for an afternoon pick-me-up, there's a solid chance you'll encounter several ultra-processed foods (UPFs) as you go about your day. But while UPFs are certainly delicious and convenient, research consistently suggests that consuming a lot of these foods in your diet isn't great for your health. In fact, a new study hammers that finding home. The findings suggest that having a diet that's heavy in UPFs could actually shorten your lifespan. These foods make up about 70 percent of our food supply, making it very tricky to avoid them entirely. But the study's findings definitely provide a little extra motivation if you're looking to cut back and find. Here's everything to know about the new data and what it could mean for you. Meet the experts: Jessica Cording, RD, CDN, is author of The Little Book of Game-Changers; Keri Gans, RDN, is author of The Small Change Diet For the study, which was published in the journal Nature Medicine, researchers followed more than 540,000 American adults between the ages of 50 and 71, and tracked their diets for nearly 30 years. More than half of the people in the study, which started in the mid-1990s, have since died. The researchers looked at the death rates of people who ate the most UPFs and those who ate the least, and also drilled down on the types of UPFs they ate. The researchers discovered that having a diet heavy in UPFs was linked to a higher risk of developing type 2 diabetes, heart disease, and colorectal cancer, along with about a 10 percent higher risk of early death. Processed meat (think: deli meat and hot dogs) was linked to an 11 percent increase in type 2 diabetes risk and a 7 percent higher risk of developing colorectal cancer. Sugar-sweetened beverages like sodas led to an 8 percent higher risk of type 2 diabetes and a 2 percent higher risk of heart disease. The researchers stressed that more research is needed, but say the findings only add to the growing recommendations that people cut back on their ultra-processed food intake. The level of processing that food undergoes before it ends up on our table is classified by a system known as the NOVA scale. This breaks foods into four categories, explains Jessica Cording, RD, CDN, author of The Little Book of Game-Changers: Unprocessed and minimally processed foods: Foods that fall into this group are in their natural state or barely altered, Cording says. That includes things like strawberries, avocados, and milk. Processed culinary ingredients: Foods in this camp are minimally processed through steps like pressing, refining, grinding, or milling. Almond flour and olive oil are processed culinary ingredients, Cording explains. Processed foods: Foods that are considered processed have been changed from their natural state and often contain salt, oil, and sugar. That includes some cheeses and canned fish, per Cording. Ultra-processed foods: These foods are processed, but take it another step by also including ingredients like artificial colors and flavors, along with preservatives for shelf stability, and ingredients to preserve texture. Packaged foods usually fall into this group. There are several things that could be at play here. For starters, UPFs are linked with a higher risk of developing serious health issues like heart disease and colorectal cancer, and having those conditions raises your risk of early death. It's likely related to inflammation, says Keri Gans, RDN, author of The Small Change Diet. 'Diets rich in ultra-processed foods may cause inflammation in the body, which over time may increase the risk of heart disease, type 2 diabetes, cancer, and other serious health issues that can reduce your lifespan,' she says. There are a few reasons why these foods aren't great for your heart. 'Ultra-processed foods are often high in added sugars, saturated fats, and sodium, which may increase blood pressure, LDL ('bad') cholesterol, and inflammation, all key risk factors for heart disease,' Gans says. But eating a lot of UPFs also means that you're likely crowding out healthier choices, Cording points out. 'If someone is eating a lot of ultra-processed foods that don't offer much in the way of important vitamins and minerals, and over-consuming sugar, preservatives, and empty calories, it can set someone up for adverse health issues,' she says. This food category is quite broad and includes things like bars and protein powders, along with stuff people typically think of, like hot dogs and sodas. While dietitians stress that whole foods are best, Cording says you don't need to freak if you grab the odd bar to tide you over until dinner. 'It's really the overall diet pattern that matters,' she says. Still, if you'd prefer to cut out or cut down on UPFs in your life, Gans recommends filling your plate with whole foods first. 'Focus on eating more whole foods, such as fruits, vegetables, whole grains, legumes, nuts, and lean proteins, which naturally leave less room for ultra-processed ones,' she says. Reading ingredients lists is also helpful, Gans adds. 'Look for lengthy lists that include added sugars, saturated fats, and excessive sodium,' she suggests. The experts also know that it's difficult to be perfect here. 'You don't have to cut everything out, but being mindful helps,' she says. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals

M&M's and Skittles maker resists RFK Jr's demand to remove synthetic dyes from candies
M&M's and Skittles maker resists RFK Jr's demand to remove synthetic dyes from candies

New York Post

timean hour ago

  • New York Post

M&M's and Skittles maker resists RFK Jr's demand to remove synthetic dyes from candies

Health Secretary Robert F. Kennedy Jr.'s campaign to eliminate synthetic food dyes from the American food supply is facing stiff resistance from one of the country's most iconic candy makers — Mars, the manufacturer of M&M's and Skittles. Mars released a statement earlier this week saying that it will continue using the synthetic dyes in its candies, reversing a pledge the company made in 2016 to remove artificial colors from all foods and snacks in its portfolio. The company insisted to the New York Times that its products are 'safe to enjoy and meet the high standards and applicable regulations set by food safety authorities around the world.' Advertisement 4 Health Secretary Robert F. Kennedy Jr has been unable to convince candy maker Mars to ban artificial food dyes. Getty Images While Mars has made incremental changes — such as eliminating titanium dioxide from Skittles — it continues to rely on artificial colorings, citing challenges with cost, limited availability of natural alternatives and consumer preferences for brightly colored treats. The National Confectioners Association, which represents candy makers, has echoed Mars' position. 'We follow and will continue to follow regulatory guidance from the authorities in this space,' spokesman Christopher Gindlesperger said. Advertisement He noted that alternatives to synthetic dyes are more expensive, harder to source, and could raise prices due to limited supply. 'Companies need time to find alternatives,' Gindlesperger said. The Post has sought comment from Kennedy, Mars and the National Confectioners Association. Advertisement 4 Mars released a statement saying it will continue using synthetic dyes in its products such as M&M's. jlmcanally – Several leading food manufacturers have recently committed to removing synthetic, petroleum-based food dyes from their products in response to mounting public health concerns and growing consumer demand for cleaner ingredients. Among the companies that have voluntarily agreed to eliminate synthetic dyes from their portfolios by the end of 2027 are Kraft Heinz, General Mills, PepsiCo, Nestlé and ConAgra Brands. Their decision follows advocacy efforts by health officials and organizations warning about potential links between artificial dyes and behavioral issues in children, as well as broader concerns over the safety of food additives. Advertisement 4 Mars has made incremental changes — such as eliminating titanium dioxide from Skittles. Brett – In contrast, the candy industry has yet to fully embrace this movement. While federal regulators have so far declined to crack down on artifical dyes, lawmakers at the state level have either introduced legislation or are considering proposals that would restrict or outright ban foods that contain synthetic coloring. West Virginia has passed one of the most sweeping laws on synthetic food dyes, banning seven dyes and two preservatives from school meals starting Aug. 1 and from all foods sold statewide by Jan. 1, 2028. 4 Mars reversed itself from a pledge it made in 2016 to phase out artificial food colorings from its entire portfolio of products. Timon – California will prohibit Red Dye No. 3 and other additives in foods beginning Jan. 1, 2027, with a separate school ban on six synthetic dyes taking effect later that year. Utah and Virginia have both enacted bans on multiple artificial dyes in foods sold or served in public schools. The Utah ban went into effect in March of last year while the Virginia ban will be effective July 1, 2027. Texas has opted for mandatory warning labels — rather than outright bans — on foods containing over 40 additives, including synthetic dyes, starting Jan. 1, 2027.

Companion Spine LLC Announces Definitive Agreement to Acquire the Business and Assets of Paradigm Spine GmbH and the Coflex® and CoFix® Spine Implants from Xtant™ Medical Holdings, Inc.
Companion Spine LLC Announces Definitive Agreement to Acquire the Business and Assets of Paradigm Spine GmbH and the Coflex® and CoFix® Spine Implants from Xtant™ Medical Holdings, Inc.

Yahoo

time2 hours ago

  • Yahoo

Companion Spine LLC Announces Definitive Agreement to Acquire the Business and Assets of Paradigm Spine GmbH and the Coflex® and CoFix® Spine Implants from Xtant™ Medical Holdings, Inc.

Strategic step to strengthen Companion Spine's global leadership in posterior dynamic spine stabilization and spine motion preservation. The combined product portfolio will reinforce Companion Spine's innovative and leading international business platform focused on the treatment of spine pain resulting from lumbar spinal stenosis and degenerative disc disease, two of the main causes of disability globally. Anticipated completion of the acquisition is in 3Q25. BORDEAUX, France & NEW YORK, July 08, 2025--(BUSINESS WIRE)--Companion Spine LLC ("Companion Spine" or "the Company"), the French-American specialist in spine pain-management surgery, announced that it has entered into a definitive agreement to acquire the Coflex® Interlaminar Stabilization® device ("Coflex®") and CoFix® Posterior MIS Fusion System ("CoFix®") implants, Paradigm Spine GmbH, its subsidiaries and all Paradigm Spine-related business activity globally ("Paradigm Spine") from Xtant™ Medical Holdings, Inc. (NYSE:XTNT) ("Xtant Medical"). Paradigm Spine GmbH is headquartered in Wurmlingen, Germany and designs, develops, markets and distributes a comprehensive range of spine implant solutions for the treatment of spine pain-related disorders. Coflex® and CoFix® are available in the United States—Paradigm Spine has been commercializing these systems for 12 years within the U.S. and 20 years outside the U.S. These are two of the most widely used, successful posterior dynamic spine stabilization implants globally, with distribution to more than 60 countries, and with more than 280,000 Coflex® devices implanted, treating more than 265,000 patients globally. More than 130,000 CoFix® systems have been used to treat more than 125,000 patients globally. The Paradigm Spine products available only outside of the U.S. are the HPS™ 2.0 Hybrid Performance System ("HPS™ 2.0"), DSS™ Dynamic Stabilization System ("DSS™") and DCI™ Dynamic Cervical Implant ("DCI™"). Together with the portfolio of Companion Spine products, including the DIAM™ Spinal Stabilization System ("DIAM™"), LISA™ Lumbar Implant for Stiffness Augmentation ("LISA™") and the APERIUS™ Percutaneous Interspinous Spacer ("APERIUS™"), the Company will be in the position to treat the full range of lumbar spinal stenosis ("LSS") and degenerative disc disease ("DDD") conditions across the spectrum of disease progression. With this acquisition, Companion Spine continues to expand its mission to safely and effectively treat spine pain through treating lumbar and cervical diseases. The Company will offer a full range of minimally invasive surgical ("MIS") implant systems tailored to each stage of the disease condition and focused on delivering the systems for use in the outpatient care setting. This acquisition positions Companion Spine to be the holder of the world's largest and most comprehensive product portfolio of MIS posterior dynamic spine stabilization and motion preserving solutions, dedicated to restoring form, function, motion, balance and stabilization while reducing or eliminating pain. This is the essence of the Company's commitment to innovation and excellence in spine care. "This is an incredible opportunity to bring together two highly complementary product offerings to enhance Companion Spine's ability to provide solutions across the full spectrum of pathological stages of LSS and DDD," said Anthony G. Viscogliosi, Executive Chairman and Chief Executive Officer of Companion Spine. "We are confident we will create value for our stakeholders, building on our shared history with the most experienced management team in posterior dynamic spine stabilization and motion preservation. Paradigm Spine was previously part of the Viscogliosi Brothers portfolio and sold in 2019. We are now re-acquiring it, bringing it back into our portfolio through Companion Spine. We know the business, its customers and its talented team very well. There is much to look forward to as we build upon this momentum to realize our vision and continue to support patients and surgeons globally." Mr. Viscogliosi continued, "Companion Spine, co-founded by former CEO Erick Cloix, may he rest in peace and joy, was formed through the acquisition of a dynamic stabilization and motion preservation product portfolio from Medtronic, which included DIAM™, APERIUS™ and other implants. Then, the Company was complemented by the acquisition of Backbone SA and its LISA™ dynamic stabilization business. Now, with the planned acquisition of Paradigm Spine, the Company will become the largest posterior and cervical dynamic stabilization franchise business in the world." Mr. Viscogliosi was elected CEO following the passing of former CEO Erick Cloix on March 29, 2025. Viscogliosi Brothers, LLC, the controlling shareholder and largest shareholder of Companion Spine, will support the acquisition close and transition period for the combined company, bringing deep domain expertise to ensure long-term business stability and growth. Already recognized leaders in disc replacement and spine fusion, the Viscogliosi Brothers continue to establish themselves also as a global leader in the posterior dynamic spine stabilization and motion preservation market through this expansion opportunity of Companion Spine. "This is a terrific transaction for both organizations," said Sean Browne, Chief Executive Officer of Xtant Medical. "For Xtant, the sale of these business units allows us to strategically focus on our core business, while meaningfully reducing our debt and improving our balance sheet. Moreover, these fantastic motion preservation technologies such as Coflex®, HPS™ 2.0 and DCI™ will get the kind of focus only the Viscogliosi Brothers and Companion Spine can provide to optimize their commercial development. This type of development is in the DNA of the Viscogliosi Brothers, while it is far afield of Xtant Medical's core competencies; so we expect big things for Companion Spine in the years ahead." The acquisition is poised to accelerate Companion Spine's global market expansion, strengthening its presence in the U.S. and enhancing its competitive positioning in high-growth international markets to create the largest footprint in the posterior dynamic spine stabilization market. It also reinforces Companion Spine's strategy, focusing on ambulatory surgery centers, catering to spine surgeons and dynamic stabilization and motion preservation specialists, and on indication-specific, U.S. FDA Premarket Approval products, with the longest clinical history of success—as seen by Coflex®'s 90% patient satisfaction and the more than 150 papers published on the device. Following the close of the acquisition, Companion Spine will become the first sole source provider of a full range of an indication-specific product portfolio for customers using dynamic stabilization and motion preservation implants. The range of products and uses include: APERIUS™ for early stage LSS, Coflex® when a decompression is required for LSS or CoFix® when a larger decompression is needed and there exists a significant amount of instability for LSS, or HPS™ 2.0 or DSS™ when there is significant instability but a desire to preserve adjacent segments. In the cervical anatomy, DCI™ is designed as a Coflex® concept applied in an anterior interbody fashion, for maintenance of motion. Lastly, Companion Spine's DIAM™ product is designed for use in DDD patients. The companies expect to complete the acquisition in the third quarter of 2025, subject to closing conditions. Innovatus Capital Partners is the current senior lender to Companion Spine. Companion Spine is advised in this acquisition by Dorsey & Whitney, LLP as lead legal counsel, McDermott Will & Emery as tax and German legal counsel, Farber LLC as intellectual property legal counsel, Natixis Partners as capital access financial advisor, FTI Consulting as strategic communications advisor, Deloitte Finance as financial due diligence advisor, MCRA as regulatory, clinical and reimbursement advisor, and UHY LLP as U.S. auditor. Xtant Medical is advised by Fox Rothschild LLP as legal counsel and LifeSci Partners as investor relations advisor. About Companion Spine Founded in 2020 in New-York, United States, and Bordeaux, France, Companion Spine is a global company specialized in the treatment of spine degenerative conditions using posterior dynamic spine stabilization and motion preserving technology while dynamically stabilizing the spine, preserving motion and reducing or eliminating spine pain. Companion Spine's comprehensive system of technologies and solutions target lumbar spinal stenosis and degenerative disc disease, two of the most common indications for back and leg pain worldwide. Companion Spine proposes a portfolio of implant systems and solutions that allows spine specialists to offer their patients earlier, safe, effective, reversible and minimally invasive alternatives to more invasive implant procedures. For more information, please visit: About Paradigm Spine Paradigm Spine is a provider of non-fusion and fusion spinal implant solutions that serve to address the unmet clinical needs of spine surgeons and their patients. Starting with the Coflex® Interlaminar Stabilization® device, Paradigm Spine develops a full non-fusion product portfolio of motion preserving, tissue sparing technologies, as well as fusion products. Their commitment is to lead the positioning of non-fusion technologies to the forefront of improving the quality of life in patients with spinal diseases through being surgeon centric, indication specific and data driven. About Xtant Medical Holdings, Inc. Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. ( is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers. The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners. About Viscogliosi Brothers, LLC Viscogliosi Brothers is a family-owned New York City-based single family office dedicated to driving growth and innovation in the neuro-musculoskeletal industry. Established in 1999, the firm focuses on identifying and building groundbreaking innovations in healthcare, aiming to address unmet clinical needs, enhance patient outcomes, and drive cost efficiency in the healthcare system. Since its inception 26 years ago, Viscogliosi Brothers has founded, financed, operated and grown 43 businesses with operations and distribution across more than 80 countries. These businesses have positively impacted millions of patients with cutting-edge innovations in healthcare. The firm has led the transformation of multiple businesses in the spine industry specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma, Woven Orthopedics Technologies and VB Spine, among others. For more information, please visit: About Viscogliosi Brothers Watermark Viscogliosi Brothers Watermark LLC is a New York City-based holding company specializing in investing in innovation within the MedTech sector. Founded in 2022, VBW is committed to creating wealth for its shareholders while enhancing humanity's well-being. With a portfolio-driven investment mandate and strategic expertise, VBW supports its invested entities through financing and manufacturing support capabilities. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; the ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to license certain of the Company's intellectual property on commercially reasonable terms and to maintain any such licenses; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. View source version on Contacts Companion Spine Anthony G. ViscogliosiExecutive Chairman and Chief Executive Officer of Companion Spineaviscogliosi@ Xtant Medical Kevin GardnerLifeSci Advisorskgardner@ -OR- Rob WindsorLifeSci Advisorsrwindsor@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store